Avammune Therapeutics key facts
as of Oct 2026- Developer of non-nucleotide small-molecule inhibitors designed for the treatment of cancer and infectious diseases.
- Avammune Therapeutics is valued at approximately $33.0M as of Oct 2026 (last reported valuation).
- It has raised $18.5M; the latest was Later Stage VC ($12.0M) in May 2025.
- Notable investors include JITO Incubation & Innovation Foundation, Shastra VC, IvyCap Ventures, The Chennai Angels, 1Crowd — 7 tracked in total.
- Status: Privately Held (backing).
Avammune Therapeutics's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·Watch Avammune Therapeutics: the Monday email on marks, rounds and moves
Avammune Therapeutics funding rounds
No funding rounds for Avammune Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Avammune Therapeutics valuation
Avammune Therapeutics's last reported valuation was $33 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
Avammune Therapeutics investors
7 investors are on record for Avammune Therapeutics, including JITO Incubation & Innovation Foundation, Shastra VC, IvyCap Ventures and The Chennai Angels.
About Avammune Therapeutics
Developer of non-nucleotide small-molecule inhibitors designed for the treatment of cancer and infectious diseases. The company develops a multimodal approach that employs a combination of engineered viruses and small molecules to modulate the pathway to treat cancer, enabling patients to harness their immune systems.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2017
- Employees
- 13
- Website
- avammune.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.